The authors concluded that in their analysis of real-world data, the effectiveness of the biosimilar was equivalent to that of the reference product in patients with Crohn disease (CD) who were naïve to therapy with infliximab, and no difference was observed in terms of safety between the 2 therapies.
Celltrion’s CT-P13, an infliximab biosimilar approved in the United States as Inflectra and in the European Union as Remsima, is widely used in the treatment of inflammatory diseases, and was approved on the basis of studies conducted in rheumatoid arthritis and ankylosing spondylitis.
An extrapolated indication was granted for the treatment of Crohn disease (CD), and since approval, numerous real-world data have supported the use of CT-P13 in patients with CD. A new study, published this week in Annals of Internal Medicine, further underscores the safety and effectiveness of CT-P13 in this disease state.
The comparative equivalence cohort study compared CT-P13 with the reference infliximab, Remicade, in patients with CD who were naïve to infliximab therapy. In total, 5050 patients aged 15 years or older were enrolled in the study, and 2551 were given the reference infliximab, while 2499 were given the biosimilar. None of the patients had other diseases with an indication for treatment with infliximab.
The study’s primary outcome was a composite end point of death, CD-related surgery, all-cause hospitalization, and reimbursement for another biologic treatment. The predefined equivalence margin (0.80-1.25) was defined as a 95% CI of the hazard ratio (HR) of CT-P13 versus the reference product in a multivariable marginal Cox model.
In total, 1147 patients in the reference group met the composite end point, with 838 hospitalizations. In the biosimilar group, 952 patients, with 719 hospitalizations, met the end point. In a multivariable analysis, CT-P13 was equivalent to the reference infliximab, with an HR of 1.10 (95% CI, 0.26-3.34).
There were no differences in safety outcomes between the 2 groups with respect to serious infection (HR, 0.82; 95% CI, 0.61-1.11), tuberculosis (HR, 1.10; 95% CI, 0.36-3.34), or malignancy (HR, 0.66; 95% CI, 0.33-1.32).
The authors concluded that in their analysis of the real-world data, the effectiveness of the biosimilar was equivalent to that of the reference product in patients with CD who were naïve to therapy with infliximab, and no difference was observed in terms of safety between the 2 therapies.
Reference
Meyer A, Rudant J, Drouin J, Weill A, Carbonnel F, Coste J. Effectiveness and safety of reference infliximab and biosimilar in Crohn disease: a French equivalence study [published online December 11, 2018]. Ann Intern Med. doi: 10.7326/M18-1512.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
What Clinicians Need to Know About Using Biosimilars to Treat IBD
April 13th 2024A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.
Biosimilars Gastroenterology Roundup for January 2024—Podcast Edition
February 4th 2024On this episode of Not So Different, we reminisce on all the major gastroenterology news from January, which brought several reports quantifying how the gastroenterology biosimilar market is progressing and marked the 1-year anniversary of adalimumab biosimilar competition in the US.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.